Evaluation results of medicines
- Daclatasvir and Asunaprevir (Daklinza and Sunvepra)
- Ledipasvir and Sofosbuvir (Harvoni)
- Nivolumab (OPDIVO)
- Ombitasvir, Paritaprevir and Ritonavir (Viekirax)
- Sofosbuvi (Sovaldi)
- Trastuzumab emtansine (Kadcyla)
Results at the trial phase (~2019)
We show results of cost-effectiveness evaluation on medicines and medical devices reported to CSIMC (Chuikyo) general assembly in Japan [trial phase].